Amphastar Pharmaceuticals, Inc. (AMPH)

Amphastar Pharmaceuticals beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 6, 2026, with adjusted EPS of $0.91 topping the $0.62 estimate (+46.8%) and revenue of $183.9 million topping the $179.9 million estimate (+2.2%). Revenue rose 5.4% to about $183.9 million (up from $174.4 million a year ago), with sales concentrated in the United States, where revenue increased 3.2% to roughly $172.3 million, while China rose 1425.1% to about $4.6 million. Profitability came through at a gross margin of 50.8% and an operating margin of 21.6%, with operating income of roughly $39.7 million and net income edging down 2.2% to about $30.3 million (from $31.0 million a year ago). Operating cash flow was about $51.3 million, and the company repurchased roughly $45.2 million of stock during the quarter. For the next period, consensus calls for EPS of $0.86 on revenue of $197.9 million.